Aytu BioPharma, Inc. (AYTU)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q3-2026 | 8-K (2026-05-13) · 99.1 | 8-K (2026-04-02) | ||
| 10-Q | Q2-2026 | 8-K (2026-02-03) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2025-11-13) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2025-09-23) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-05-14) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-02-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2024-11-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2024-09-26) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-05-15) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-02-14) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2023-11-14) · 99.1 | 8-K (2023-10-26) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2023-09-27) · 99.1 | ||
| 10-Q/A | Q1-2023 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (current Period Unaudited) | — |
|
| Unaudited Consolidated Balance Sheets | — |
|
| Consolidated Balance Sheets (current Period Unaudited) (P) | — |
|
| Consolidated Balance Sheets (P) | ||
| Unaudited Consolidated Balance Sheets (P) | — |
|
| Consolidated Statements of Operations | ||
| Unaudited Consolidated Statements of Operations | — |
|
| Unaudited Consolidated Statements of Stockholders' Equity | — |
|
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Stockholders' Equity (P) | — |
|
| Consolidated Statements of Cash Flows | ||
| Unaudited Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued Liabilities | ||
| Capital Structure | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Employee Benefit Plan | — |
|
| Equity Incentive Plans | ||
| Fair Value Considerations | — |
|
| Fair Value Measurements | — |
|
| Goodwill and Other Intangible Assets | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Intangible Assets | — |
|
| Inventories | ||
| Leases | ||
| License Agreements | ||
| Line of Credit | ||
| Long-term Debt | ||
| Nature of Business and Financial Condition | — |
|
| Nature of Business, Financial Condition, Basis of Presentation | — |
|
| Net Loss Per Common Share | — |
|
| Note 1 | ||
| Note 10 | ||
| Note 11 | ||
| Note 12 | ||
| Note 13 | ||
| Note 14 | ||
| Note 15 | ||
| Note 16 | ||
| Note 17 | ||
| Note 18 | ||
| Note 19 | ||
| Note 2 | ||
| Note 20 | ||
| Note 21 | — |
|
| Note 3 | ||
| Note 4 | ||
| Note 5 | ||
| Note 6 | ||
| Note 7 | ||
| Note 8 | ||
| Note 9 | ||
| Other Liabilities | ||
| Property and Equipment | ||
| Revenues From Contracts With Customers | ||
| Segment Information | — |
|
| Significant Accounting Policies | — |
|
| Stockholders Equity | — |
|
| Subsequent Events | — |
|
| Summary of Significant Accounting Policies | — |
|
| Warrants | ||